PEG10 is associated with treatment-induced neuroendocrine prostate cancer

Clinical and molecular features of treatment-related neuroendocrine prostate cancer

(2018) Shusuke Akamatsu et al.   INTERNATIONAL JOURNAL OF UROLOGY

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

(2018) Rahul Aggarwal et al.   JOURNAL OF CLINICAL ONCOLOGY

PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer

(2017) Yun-Peng Peng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer

(2016) Etienne Dardenne et al.   CANCER CELL

PEG10 promotes human breast cancer cell proliferation, migration and invasion

(2016) XINRAN LI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

(2016) Jennifer L. Bishop et al.   Cancer Discovery

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer

(2015) X. Zhang et al.   CLINICAL CANCER RESEARCH

Regulation of tumor cell plasticity by the androgen receptor in prostate cancer

(2015) J. L. Bishop et al.   ENDOCRINE-RELATED CANCER

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer

(2015) Shusuke Akamatsu et al.   Cell Reports

Aggressive Variants of Castration-Resistant Prostate Cancer

(2014) H. Beltran et al.   CLINICAL CANCER RESEARCH

Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

(2013) H.-L. Tan et al.   CLINICAL CANCER RESEARCH

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

(2013) Prabhakar Rajan et al.   EUROPEAN UROLOGY

A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo

(2013) H. Kuruma et al.   MOLECULAR CANCER THERAPEUTICS

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

(2013) M. Korpal et al.   Cancer Discovery

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

Overcoming mutation-based resistance to antiandrogens with rational drug design

(2013) Minna D Balbas et al.   eLife

Specific changes in the expression of imprinted genes in prostate cancer—implications for cancer progression and epigenetic regulation

(2012) Teodora Ribarska et al.   ASIAN JOURNAL OF ANDROLOGY

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features

(2011) V. Tzelepi et al.   CLINICAL CANCER RESEARCH

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery